Posted by Michael Wonder on 16 Jun 2022
Savara awarded innovation passport in United Kingdom for molgramostim nebuliser solution, a novel investigational inhaled biologic
16 June 2022 - Innovation passport awarded to molgramostim for the treatment of auto-immune pulmonary alveolar proteinosis, a rare lung disease.
Savara today announced molgramostim has been awarded an Innovation Passport for the treatment of auto-immune pulmonary alveolar proteinosis by the UK’s MHRA.
Innovation passport is the entry point to the ILAP, a novel program aimed at accelerating the time to market and facilitating patient access to medicines in the UK.
